Compass-Logo-Black++(1).png
Compass Pathways to participate in three investor conferences in September
August 28, 2024 06:00 ET | Compass Pathways
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass-Logo-Black++(1).png
COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference
August 06, 2024 08:00 ET | Compass Pathways
LONDON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass-Logo-Black++(1).png
Compass Pathways announces second quarter 2024 financial results and business highlights
August 01, 2024 06:30 ET | Compass Pathways
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori...
Compass-Logo-Black++(1).png
Compass Pathways to announce second quarter financial results on August 1, 2024
July 24, 2024 07:01 ET | Compass Pathways
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass-Logo-Black++(1).png
Compass Pathways appoints Lori Englebert as Chief Commercial Officer
June 26, 2024 06:30 ET | Compass Pathways
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key...
Compass-Logo-Black++(1).png
Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 24, 2024 16:01 ET | Compass Pathways
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass-Logo-Black++(1).png
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
May 08, 2024 06:45 ET | Compass Pathways
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces...
Compass-Logo-Black++(1).png
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
May 08, 2024 06:30 ET | Compass Pathways
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5...
Compass-Logo-Black++(1).png
Compass Pathways to announce first quarter financial results on May 8, 2024
May 03, 2024 16:58 ET | Compass Pathways
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass-Logo-Black++(1).png
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
May 02, 2024 06:30 ET | Compass Pathways; Mindful Health Solutions
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...